Raymond James Lowers Danaher (NYSE:DHR) Price Target to $275.00

Danaher (NYSE:DHR) had its target price decreased by analysts at Raymond James from $300.00 to $275.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the conglomerate’s stock. Raymond James’ price target suggests a potential upside of 12.62% from the stock’s previous close.

DHR has been the topic of a number of other reports. Citigroup lowered their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Finally, Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Trading Up 0.0 %

Danaher stock opened at $244.19 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The stock has a market cap of $176.38 billion, a P/E ratio of 46.60, a PEG ratio of 4.30 and a beta of 0.83. The firm’s fifty day moving average price is $234.84 and its 200-day moving average price is $253.53.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period in the prior year, the company earned $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities research analysts forecast that Danaher will post 7.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently bought and sold shares of DHR. Coronation Fund Managers Ltd. increased its position in Danaher by 29.9% during the 2nd quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after purchasing an additional 1,470 shares during the period. ProShare Advisors LLC boosted its stake in shares of Danaher by 7.9% during the 2nd quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock valued at $24,118,000 after purchasing an additional 7,091 shares in the last quarter. Mount Yale Investment Advisors LLC increased its position in shares of Danaher by 43.8% during the second quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock valued at $660,000 after buying an additional 805 shares during the period. EverSource Wealth Advisors LLC raised its stake in Danaher by 12.1% in the second quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the conglomerate’s stock worth $424,000 after buying an additional 165 shares in the last quarter. Finally, DRW Securities LLC purchased a new stake in Danaher in the second quarter worth about $385,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.